Pacira BioSciences, Inc.
PCRX· Nasdaq
Released Apr 30, 2026, after the close
10-Q filed Apr 30, 2026, 30 days after period end · 0001628280-26-028871
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $177.38M | $168.92M | $167.12M | $160.34M |
| Net Income | $2.92M | $4.81M | $8.98M | -$19.54M |
| EPS Diluted |
Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR
| $0.07 |
| $0.10 |
| $0.19 |
| -$0.43 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.